Oculis Holding AG (OCS) Return on Capital Employed (2023 - 2026)
Oculis Holding AG's (OCS) quarterly Return on Capital Employed came in at 31.8% in Q1 2026, up 1648.0% year-on-year from 1.82% in Q1 2025, and up 10.2% quarter-over-quarter from 35.41% in Q4 2025.
Oculis Holding AG (OCS) Return on Capital Employed (2023 - 2026) Analysis & Trends
Oculis Holding AG's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 31.8% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 1648.0% year-over-year to 31.8% in Q1 2026; TTM through Mar 2026 was 31.8%, a 1648.0% increase from a year earlier, with the FY2025 full-year figure at 59.21%, up 4254.0% from the prior year.
- Return on Capital Employed climbed to 31.8% in Q1 2026 per OCS's latest filing, from 35.41% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.8% in Q1 2026 and bottomed at 76.62% in Q4 2023.
- The 4-year median for Return on Capital Employed is 48.28% (2025), against an average of 52.66%.
- Across the five-year window, Return on Capital Employed surged 808 bps in 2024 and surged 3312 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 76.62% in 2023, then increased by 11 bps to 68.53% in 2024, then surged by 48 bps to 35.41% in 2025, then rose by 10 bps to 31.8% in 2026.
- Per Business Quant, the three latest OCS Return on Capital Employed figures stand at 31.8% (Q1 2026), 35.41% (Q4 2025), and 38.87% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 20.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.80% |
| Dec 31, 2025 | -35.41% |
| Sep 30, 2025 | -38.87% |
| Jun 30, 2025 | -37.43% |
| Mar 31, 2025 | -48.28% |
| Dec 31, 2024 | -68.53% |
| Sep 30, 2024 | -47.94% |
| Jun 30, 2024 | -66.13% |
| Mar 31, 2024 | -57.80% |
| Dec 31, 2023 | -76.62% |
| Sep 30, 2023 | -70.48% |